Home / Health / GLP-1s: Real-World Data Eases Cessation Fears
GLP-1s: Real-World Data Eases Cessation Fears
18 Mar
Summary
- New study suggests minimal weight regain after stopping GLP-1s.
- Real-world data shows patients often switch or restart medications.
- Continued healthcare engagement aids weight maintenance post-treatment.
Millions using injectable GLP-1 medications such as Ozempic and Wegovy may wonder about the consequences of discontinuing treatment. Previous clinical trials suggested a significant "rebound" effect, where lost weight was quickly regained. However, recent research from Cleveland Clinic, published in Diabetes, Obesity and Metabolism, provides a more optimistic outlook.
The study examined nearly 8,000 adults who stopped semaglutide or tirzepatide after using them for three to twelve months. Unlike controlled trials, this research focused on real-world outcomes. It found that patients did not experience substantial weight regain in the year following cessation. For those treated for obesity, an average of 8.4% weight loss was followed by only a 0.5% regain one year later.
Researchers attribute this improved outcome to patients actively managing their treatment. Approximately 27% transitioned to different medications, and 20% restarted their original prescription once issues like insurance or side effects were resolved. Another 14% joined intensive lifestyle modification programs. Patients who maintained their weight generally remained connected with healthcare providers or followed structured support systems.
